

The 1st International Standard for Colistin Methane Sulfonate

NB: Since April 2006, the European Directorate for the Quality of Medicines & HealthCare (EDQM-Council of Europe) is in charge of the establishment and distribution of International Standards for Antibiotics instead of the National Institute for Biological Standards and Control (NIBSC-UK).

1. Introduction

The 1st International Standard for Colistin Methane Sulfonate was established by the WHO Expert Committee on Biological Standardisation at its 19th meeting in 1967¹. It consists of ampoules each containing approximately 75 mg of colistin methane sulfonate, 12700 International Units per mg and the International Unit of Colistin Methane Sulfonate is defined as the activity contained in 0.0007874 mg of the 1st International Standard of Colistin Methane Sulfonate. Colistin Methane Sulfonate is also known as "Colistin Sulphomethate" or as "Colistimethate".

2. Biological Activity

The 1st International Standard of Colistin Methane Sulfonate (code-labelled 66_254) was calibrated by 7 laboratories against 6 national standards in an international collaborative study². A total of 148 individual assays were carried out by plate diffusion methods. Two different test organisms were used in the study, (*B. brontiseptica* and *E. coli*). The potency agreed by the participants was **12700 International Units per mg**.

3. Caution

For laboratory use only. Handle in accordance with good occupational hygiene, safety and laboratory practices and take precautions to avoid exposure. This material is not for administration to humans or animals. The corresponding safety data sheet can be accessed via the EDQM website (Reference Standards Database) or is available upon request from the EDQM (Helpdesk-FAQ section).

4. Further Information

Preparation of the reference standard

The bulk material consisted of a single batch of colistin methane sulfonate, stored in sealed containers at -10°C in the dark until required for filling. In July 1966 it was allowed to warm to room temperature overnight being thoroughly mixed during that period. It was then distributed in approximately 75 mg quantities into neutral glass ampoules and dried at room temperature over P₂O₅ *in vacuo* to constant weight. The ampoules were then filled with pure dry nitrogen, sealed by fusion of the glass, tested for leaks and finally placed on storage at -20°C in the dark.

The ampouled material

The batch consisted of about 2400 ampoules, each ampoule containing approximately 75 mg of colistin methane sulfonate. The mean residual moisture content of the material in the sealed ampoules was found to be 0.44% w/w². The contents of the ampoule are hygroscopic. When exposed to an atmosphere of 45% relative humidity, samples increased in weight by approximately 0.21% w/w in 5 minutes to a total of 1.67% w/w in 60 minutes². Care should therefore be exercised in weighing out material from the ampoule to avoid error due to uptake of moisture.

Stability and Storage

It is the policy of WHO not to assign an expiry date to their International Standard. They remain valid with the assigned potency and status until withdrawn or amended.

The 1st International Standard of Colistin Methane Sulfonate is a stable preparation when stored in unopened ampoules in the dark at -20°C or below.



Acknowledgements are made to:

Kakayu Antibiotics Research Co. Ltd., Tokyo, Japan for generously supplying the material and to the participants in the collaborative study for calibrating the 1st International Reference Preparation.

References

1) World Health Organisation, Expert Committee on Biological Standardisation, WHO Technical Report Series, 1967, **361**, 11.

2) Lightbown, J.W., Bond, Jillian M., and Grab, B. (1973). Bulletin of the World Health Organisation (1973) **48**, 75-80

5. Citation

In all publications (or data sheets for kits) in which this Standard is used as an assay calibrant, it is more important that the title of the Standard, code and the name and addresses of EDQM are cited correctly.

6. Product liability

The Council of Europe accordingly makes no representation, contractual statement, or expression of opinion concerning the quality or safety of any item supplied, the presence of any defect in it, or its fitness for any particular purpose. The product must be handled by professional persons having technical skill and at their own discretion and risk. It is for the purchasers of any such item who are responsible for persons in a workplace to determine independently the risks associated with the item according to the conditions of use and to take appropriate safety measures, including provision of appropriate information to persons working with the substance. Any liability of the Council of Europe for injury, loss or damage arising from the supply or use of any such item is in any event hereby excluded to the fullest extent permitted by law; in particular, no liability is accepted for loss of profits or indirect or consequential loss.

7. Disputes

In accordance with the provisions of article 21 of the General Agreement on the Privileges and Immunities of the Council of Europe, all disputes between the Council of Europe (EDQM) and the customer as regards the application of this contract shall be submitted, if a mutual agreement cannot be reached between the parties, to arbitration as laid down in Order No. 481 of the Secretary General, approved by the Committee of Ministers.

8. Signature

This document is electronically signed by:

Dr Pierre Leveau
Head of the Quality, Safety and Environment Division